173
Participants
Start Date
October 9, 2017
Primary Completion Date
July 6, 2020
Study Completion Date
July 6, 2020
Ga-68-PSMA-11
Single administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg. A 2nd administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg is possible in the unlikely case of a negative histological result (i.e. no prostate-specific membrane antigen (PSMA) expression in dissected lymph nodes) to verify if PSMA PET-positive tissue as seen on day 1 has not been removed during RP with EPLND.
Medizinische Universität Innsbruck, Innsbruck
Universität Duisburg-Essen, Essen
Universitätsklinikum Heidelberg, Heidelberg
Eberhard-Karls-Universität Tübingen, Tübingen
Albert-Ludwigs-Universität Freiburg, Freiburg im Breisgau
Technische Universität München Klinikum rechts der Isar, München
Friedrich-Alexander-Universität Erlangen, Erlangen
Universitätsklinikum Carl Gustav Carus Dresden, Dresden
Collaborators (1)
ABX CRO
OTHER
Friedrich-Alexander-Universität Erlangen-Nürnberg
OTHER
University Hospital Freiburg
OTHER
German Cancer Research Center
OTHER